Related Experiment Video
Updated: Jul 22, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
P H O'Donnell1,2,3, N Wadhwa4, K Danahey2,5
1Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Clinical Pharmacology and Therapeutics
|April 12, 2017
Summary
Integrating pharmacogenomic (PGx) testing into clinical decision support (CDS) significantly influences provider prescribing behaviors. High-risk PGx medications were avoided, improving patient safety and demonstrating the value of genomic medicine integration.
Area of Science:
- Pharmacogenomics
- Clinical Decision Support
- Genomic Medicine Integration
Background:
- Genomic discoveries require behavioral changes for clinical practice implementation.
- Preemptive pharmacogenomic genotyping provides actionable genetic insights for patient care.
Purpose of the Study:
- To evaluate the impact of pharmacogenomic alerts on healthcare provider prescribing behaviors.
- To assess the effectiveness of a clinical decision support (CDS) system in integrating pharmacogenomic data into clinical workflows.
Main Methods:
- Prospective study analyzing 2,279 outpatient encounters across eight medical specialties.
- Utilized an institutional CDS system presenting pharmacogenomic results via traffic light alerts (green, yellow, red).
- Primary endpoint: influence of pharmacogenomic alerts on medication prescribing changes.
Main Results:
- Medications with high pharmacogenomic risk were significantly more likely to be changed (OR = 26.2, P < 0.0001).
- Medications with cautionary pharmacogenomic information were also changed more frequently (OR = 2.4, P < 0.0001).
- No high-risk pharmacogenomic medications were prescribed when physicians used the CDS tool.
Conclusions:
- Clinical integration of pharmacogenomic information via CDS enhances prescription decision-making.
- Pharmacogenomic alerts effectively guide providers to reduce patient risk.
- Genomic medicine implementation is achievable, leading to improved prescribing patterns and patient safety.
More Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).